Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion.

ABSTRACT: Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the most advanced technological methods, employing electrochemiluminescence or homogeneous time resolved fluorescence (HTRF) detection, were not capable of detecting the suppression induced by a glucose clamp (6 mmol/L) with or without atropine in five healthy male participants, whereas a radioimmu

SUBMITTER: Wewer Albrechtsen NJ 

PROVIDER: S-EPMC4709665 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature